Credit Suisse’s Amicus Therapeutics FOLD Stock Holding History

Credit Suisse’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-22,900	Closed	-$529K	–	4385
2020 Q4	$529K	Buy	+22,900	New	+$468K	﹤0.01%	3769
2018 Q4	–	Sell	-32,800	Closed	-$397K	–	3914
2018 Q3	$397K	Sell	32,800 -285,000	-90%	-$3.99M	﹤0.01%	3411
2018 Q2	$4.96M	Sell	317,800 -876,800	-73%	-$13.3M	﹤0.01%	1741
2018 Q1	$18M	Buy	1,194,600 +369,200	+45%	+$5.62M	0.02%	912
2017 Q4	$11.9M	Buy	+825,400	New	+$11.3M	0.01%	1158

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Credit Suisse's FOLD Position: Q1 2024 in Review

Credit Suisse reduced its Amicus Therapeutics (FOLD) stake by 1.1% in Q1 2024, selling an estimated $47K and leaving 322,544 shares worth $3.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1458.

Credit Suisse first reported a position in FOLD in Q2 2013 and has held it in 44 quarters since. The position peaked at $13.8M in Q3 2017. 254 funds tracked by Wall St. Rank hold FOLD as of Q1 2024.

Credit Suisse held 322,544 shares of Amicus Therapeutics worth $3.8M as of Q1 2024.
Credit Suisse sold 3,673 Amicus Therapeutics shares in Q1 2024, an estimated $47K.
Amicus Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1458 holding.
Credit Suisse first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 44 quarters since.
Credit Suisse's Amicus Therapeutics position peaked at $13.8M in Q3 2017.
254 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.